Literature DB >> 21985533

Comparison of two shampoos for the treatment of canine Malassezia dermatitis: a randomised controlled trial.

L Maynard1, C A Rème, S Viaud.   

Abstract

OBJECTIVES: Two antimicrobial shampoos for treatment of canine Malassezia dermatitis (CMD) were compared in a prospective, randomised, single-blinded, field clinical trial.
METHODS: Sixty-seven dogs with pedal or generalised dermatitis associated with Malassezia overgrowth (MO) were treated with 3% chlorhexidine shampoo (3%CHX) or 2% miconazole-2% chlorhexidine shampoo (2%MIC/CHX) and evaluated for up to 6 weeks until cytological recovery. Pruritus, erythema, papules, greasy seborrhoea, scaling, malodour, excoriations, secondary hairloss, lichenification, hyperpigmentation and lesion extent were each scored on a 0-3 severity scale and combined making an aggregate score.
RESULTS: Among 54 dogs with good treatment compliance, reduction of yeast counts by at least 88% was recorded in 21 of 22 dogs with 3%CHX and 30 of 32 dogs with 2%MIC/CHX. No significant difference was detected between products for yeast count reduction (P=0·592). Time to cytological recovery was not significantly different between groups (P=0·960). Lesion score was significantly reduced in both groups after treatment (72·5 ±25·7% with 3%CHX versus 78·7 ±22·3% with 2%MIC/CHX, P=0·309). Four dogs treated with chlorhexidine shampoo showed minor adverse effects. CLINICAL SIGNIFICANCE: In this study, 3%CHX was clinically as effective as 2%MIC/CHX for treatment of CMD.
© 2011 British Small Animal Veterinary Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985533     DOI: 10.1111/j.1748-5827.2011.01124.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  2 in total

Review 1.  Canine Malassezia dermatitis.

Authors:  Jangi Bajwa
Journal:  Can Vet J       Date:  2017-10       Impact factor: 1.008

Review 2.  Malassezia Yeasts in Veterinary Dermatology: An Updated Overview.

Authors:  Jacques Guillot; Ross Bond
Journal:  Front Cell Infect Microbiol       Date:  2020-02-28       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.